Breaking Down Axsome Therapeutics: 19 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Axsome Therapeutics (NASDAQ:AXSM) has received mixed analyst ratings over the past three months, with a majority being bullish or somewhat bullish. The average 12-month price target has slightly increased to $128.05. Despite impressive revenue growth, the company faces challenges with profitability and asset utilization.
October 04, 2024 | 6:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics has received predominantly bullish analyst ratings, with a slight increase in the average price target to $128.05. The company shows strong revenue growth but faces profitability challenges.
The majority of analysts are bullish or somewhat bullish on Axsome Therapeutics, indicating positive sentiment. The slight increase in the average price target suggests optimism about future performance. However, the company's profitability challenges may temper this optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100